NEW YORK, May 13, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new ...
Massive Bio has partnered with OpenAI to automate and scale patient pre-screening for oncology and haematology clinical trials worldwide. The collaboration uses AI to convert complex eligibility ...
Neuro-symbolic, multi-agent AI system achieves 4x faster trial matching with oncologist-confirmed accuracy across 17,000+ matches, published in ESMO Real World Data and Digital Oncology special issue ...
SAN DIEGO--(BUSINESS WIRE)--Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a ...
The materials will be made available in the Publications section of Nuvation Bio’s website after the presentation. About Taletrectinib Taletrectinib is an oral, potent, central nervous system-active, ...
(MENAFN- EIN Presswire) EINPresswire/ -- Massive Bio Publishes Peer-Reviewed Prospective Study Demonstrating AI Clinical Trial Matching Four Times Faster Than Conventional Methods Study in ESMO Real ...
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results